Press releases

New major order from China

Regulatory

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered before the end of the year and generate revenues in the fourth quarter of approximately SEK 10 million.In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead at an initial value of over 30 million. At...

CE-mark opens the door to billion-dollar market for orthopaedic trauma implants

Regulatory

Orthopaedic trauma implants in titanium with Bactiguard's coating for infection prevention have been CE marked and can, from now on, be sold and used in markets that apply EU quality standards. At the same time, the CE-mark opens possibilities for Bactiguard to establish new license agreements covering more markets. The global market for trauma...

Interim report for Q3 2018

Regulatory

Stable development following a very strong second quarterFollowing a very strong second quarter, the third quarter was a bit calmer, which is natural. Total revenues were somewhat higher than last year primarily due to increased license revenues from our largest partner BD, while BIP sales were lower. It is therefore reassuring that, so far this...

Nomination Committee appointed for the Annual General Meeting 2019

Regulatory

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 15 May 2019 at the company’s headoffice in Botkyrka, has been appoined. The Nomination Committee for the 2019 AGM in Bactiguard Holding AB (publ) will consist of the following members: Jan Ståhlberg, Chairman of the...

Interim report for Q2 2018

Regulatory

The second quarter of 2018 was eventful and financially strong, both revenue and profitability wise. Sales increased by more than 40 percent, driven by more than a doubling in sales of our own product portfolio. We also signed a combined distribution and licensing agreement for China that contributed new licensing revenues. We generated an EBITDA...

Bactiguard takes the next step in China and signs agreement worth more than SEK 30 million

Regulatory

Bactiguard takes the next step in China and accelerates its ambitions through a combined distribution and license agreement with Well Lead Medical (Well Lead) with an initial value of more than SEK 30 million. At the same time, the cooperation with the current distributor Jian AN is terminated and Bactiguard pays a compensation of approximately...

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 16 May, 2018 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2017 and decided that no dividend for the financial year 2017 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...

Interim report for Q1 2018

Regulatory

In 2018, our primary focus is to generate growth through increased sales of our own product portfolio and by developing new licensing businesses, to approach our financial targets, and contribute to saving more lives. Therefore, it is gratifying that we can already report a strong growth in sales of our own product portfolio, which more than...

Bactiguard’s Annual Report 2017

Regulatory

The annual report for Bactiguard Holding AB (publ) 2017 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 11 and can be ordered at info@bactiguard.se. This information is information that Bactiguard Holding AB...

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in March and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...

Year-end report 2017 Bactiguard Holding AB

Regulatory

2017 was a good year for Bactiguard. Our objective was to generate growth, with sustained cost control, to approach our long-term financial targets of 20 percent growth and an EBITDA margin of 30 percent. It is therefore gratifying that sales for the full year amounted to close to MSEK 154, which means growth of 20 percent, quite in line with our...

The Nomination Committee proposes that Jan Ståhlberg is elected new member of the Board and Chairman of Bactiguard Holding AB (publ)

Regulatory

The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes that the Annual General Meeting 2018 elects Jan Ståhlberg as new member and Chairman of the Board, as Stanley Brodén who has been the Chairman of the Board since 2015 has declined reelection. Jan Ståhlberg is Vice Chairman of EQT AB and has been active in EQT since...